T Cell News and Research

Latest T Cell News and Research

Macrogenics' Protege Phase 3 clinical study of teplizumab in type 1 diabetes published in The Lancet

MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, announced the publication in The Lancet of results from Protege, a Phase 3 clinical study of teplizumab in type 1 diabetes.

29 Jun 2011

Rodent olfaction and the chemistry of instinct

The mechanics of instinctive behavior are mysterious. Even something as simple as the question of how a mouse can use its powerful sense of smell to detect and evade predators, including species it has never met before, has been almost totally unknown at the molecular level until now.

29 Jun 2011

Nuvilex to continue development of acquired live-cell encapsulation technology

Nuvilex, Inc. announced its plans to continue development of the live-cell encapsulation technology obtained with its recent acquisition of SG Austria, to carry out the pancreatic cancer clinical trial, to maintain and expand customers utilizing the encapsulation technology, and to establish itself as an active participant in the stem cell arena. The stem cell market was estimated to be $21.5 billion globally in 2010 and is forecast to reach $63.8 billion by 2015.

29 Jun 2011

Genetic tools that enable cell type-specific delivery hold promise for combating incurable neurologic diseases

Novel tools and methods for delivering therapeutic genes to cells in the central nervous system hold great promise for the development of new treatments to combat incurable neurologic diseases. Five of the most exciting developments in this rapidly advancing field are presented in a series of articles in the June issue of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc..

29 Jun 2011

Start of clinical validation study of Down’s syndrome diagnostic test

In conjunction with several Central European prenatal centers, scientists at GATC Biotech AG and LifeCodexx AG have begun the clinical validation study of a non-invasive, prenatal diagnostic test based on next generation sequencing.

28 Jun 2011

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Tibotec Pharmaceuticals today announced that it has entered into a license agreement with Gilead Sciences, Inc., for the development and commercialization of a new once-daily single tablet fixed-dose antiretroviral combination product containing Tibotec's protease inhibitor PREZISTA® (darunavir) and Gilead's cobicistat, an investigational pharmacoenhancing or "boosting" agent.

28 Jun 2011

FDA accepts Pfizer's filing for axitinib review for advanced renal cell carcinoma

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Pfizer's filing for standard review of axitinib for patients with advanced renal cell carcinoma (RCC).

28 Jun 2011

Protein c-JUN protects both tumour accelerating gene and tumour suppressor gene

The process of cell division is tightly regulated, as mistakes may lead to cancer. The so-called c-JUN protein has been fingered as causing tumours in both skin and liver. It has long been known to have a direct role in reducing the expression of a gene (p53) that leads to the death of abnormal cells and to activate transcription of a further gene (CyclinD1) that directly promotes cell division.

28 Jun 2011

RCSI researchers identify novel drug target for osteomyeltitis

New research from the Royal College of Surgeons in Ireland (RCSI) has identified a novel drug target for the treatment of infection in bone.

28 Jun 2011

Pfizer to present PF-299 and crizotinib clinical trial data on ALK at WCLC 2011

Pfizer Inc. will present early and mid-stage data from its lung cancer portfolio, including PF-00299804 an investigational, oral, pan-HER inhibitor; and crizotinib, an investigational, oral, first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK, at the International Association for the Study of Lung Cancer's 14th World Conference on Lung Cancer, July 3-7 in Amsterdam, The Netherlands.

28 Jun 2011

Golden Rule Insurance offers summer travel tips

Summer is here and it's time to get away. But while you are making vacation plans, take a few minutes to think about what you might do if an unexpected medical emergency should occur, especially if you are traveling away from home.

28 Jun 2011

CTI added to Russell's U.S. indexes

Cell Therapeutics, Inc. announced today that it has been added to the Russell 3000, Russell 2000 and Russell Global Indexes posted by Russell Investments on June 27, 2011.

28 Jun 2011

DSM introduces Kremer Method for rapid, cost effective production of biopharmaceuticals

Royal DSM, the global Life Sciences and Materials Sciences company, today announced the introduction of the Kremer Method, an innovative proprietary technology developed by DSM scientists which improves downstream processing of monoclonal antibodies (mAbs) for faster and more cost effective production of biopharmaceuticals

28 Jun 2011

Experts discuss therapeutic potential of adipose-derived stem cells at ICAS Conference

Esthetic therapies with stem cells from autologous fat are revolutionizing cosmetic surgery: Ever more women prefer breast augmentations with autologous stem cells over silicone implants. The world's leading experts recently met at the ICAS Conference in Istanbul to discuss the therapeutic potential of stem cells from fat tissue.

28 Jun 2011

Scientists discover origin of Barrett's esophagus

Dr Frank McKeon, Senior Group Leader of the Stem Cell and Developmental Biology at A*STAR's Genome Institute of Singapore, and Principal Investigator Dr Wa Xian at A*STAR's Institute of Medical Biology, together with their counterparts from the Harvard Medical School, the Brigham and Women's Hospital in Boston, and the National University of Singapore, have made the striking finding that Barrett's esophagus work, published online in the journal Cell on 24 June 2011, is essential to developing therapeutics for esophageal cancer.

28 Jun 2011

Tissue-engineered blood vessels from donor skin cells successfully implanted in patients

For the first time, blood vessels created in the lab from donor skin cells were successfully implanted in patients. Functioning blood vessels that aren't rejected by the immune system could be used to make durable shunts for kidney dialysis, and potentially to improve treatment for children with heart defects and adults needing coronary or other bypass graft surgery.

28 Jun 2011

TrialNet presents Diamyd Phase II study results on type 1 diabetes at ADA 2011

The American research consortium Type 1 Diabetes TrialNet presented their results of a Phase II study with the antigen-based diabetes therapy Diamyd yesterday, June 27, at the American Diabetes Association 71st Scientific Sessions (ADA) in San Diego, California, USA, after the closing of the stock market.

28 Jun 2011

Marshall Edwards' Triphendiol pre-clinical study data now available in Anti-Cancer Drugs website

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from pre-clinical studies of Triphendiol, a prodrug of the Company's lead drug candidate NV-143, that demonstrate its anti-proliferative activity in pancreatic cancer as both a monotherapy and as a chemosensitizer.

28 Jun 2011

Researchers identify new lung stem cell that helps repair large airways

Researchers at UCLA have identified a new stem cell that participates in the repair of the large airways of the lungs, which play a vital role in protecting the body from infectious agents and toxins in the environment.

28 Jun 2011

New strategies for minimising the consequences of preterm babies

Babies born prematurely could be at greater risk of developing kidney diseases later in life according to a landmark study investigating the impacts of preterm birth on kidney development.

28 Jun 2011

T Cell News and Research

Latest T Cell News and Research

Macrogenics' Protege Phase 3 clinical study of teplizumab in type 1 diabetes published in The Lancet

Rodent olfaction and the chemistry of instinct

Nuvilex to continue development of acquired live-cell encapsulation technology

Genetic tools that enable cell type-specific delivery hold promise for combating incurable neurologic diseases

Start of clinical validation study of Down’s syndrome diagnostic test

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

FDA accepts Pfizer's filing for axitinib review for advanced renal cell carcinoma

Protein c-JUN protects both tumour accelerating gene and tumour suppressor gene

RCSI researchers identify novel drug target for osteomyeltitis

Pfizer to present PF-299 and crizotinib clinical trial data on ALK at WCLC 2011

Golden Rule Insurance offers summer travel tips

CTI added to Russell's U.S. indexes

DSM introduces Kremer Method for rapid, cost effective production of biopharmaceuticals

Experts discuss therapeutic potential of adipose-derived stem cells at ICAS Conference

Scientists discover origin of Barrett's esophagus

Tissue-engineered blood vessels from donor skin cells successfully implanted in patients

TrialNet presents Diamyd Phase II study results on type 1 diabetes at ADA 2011

Marshall Edwards' Triphendiol pre-clinical study data now available in Anti-Cancer Drugs website

Researchers identify new lung stem cell that helps repair large airways

New strategies for minimising the consequences of preterm babies

Immunology eBook

A new method to measure intracellular water in biological systems

Obesity, GLP-1s, and metabolic care

Automation in cell-based workflows

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

A new method to measure intracellular water in biological systems

Obesity, GLP-1s, and metabolic care

Automation in cell-based workflows

Newsletters you may be interested in